Micrograph News and Research

RSS

SARS-CoV-2 started spreading in the United States in January, CDC says

The United States has reported the highest number of infections across the globe, with more than 1.81 million confirmed cases and at least 105,000 deaths. The magnitude of the novel coronavirus spread hints that the virus may have started earlier than previously thought.

2 Jun 2020

Computer modeling reveals necessary vaccine efficacy threshold to prevent SARS-CoV-2 spread

A recent US study showed that in order to prevent or largely extinguish the coronavirus disease 2019 (COVID-19) outbreak without social distancing or any other measures, any vaccine would have to have an efficacy of at least 70%. The research paper is currently available on the medRxiv* preprint server.

1 Jun 2020

No specific COVID-19-linked lesions found despite extensive organ injury

A recent paper published online on the preprint server medRxiv in May 2020 reports autopsy results on COVID-19 patients. The paper concludes that there were no specific hallmark lesions of COVID-19 in any of the many organs found to be injured by the infection in patients who died of the disease.

1 Jun 2020

Significant number of COVID-19 positive cases asymptomatic, raising transmission concerns

There have been many instances of people testing positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) who have no symptoms of the infection whatsoever. These asymptomatic patients are, however, still capable of spreading the infection without being aware of it, say experts.

31 May 2020

Ruxolitinib shows promise in severe COVID-19

An anti-inflammatory drug Ruxolitinib has shown promising results in the treatment of severe coronavirus disease COVID-19. The study titled, “Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial,” was published as a pre-proof for the Journal of Allergy and Clinical Immunology.

31 May 2020

Rare deadly disease linked to coronavirus infection seen in children

Now, new evidence has shown that children with coronavirus disease (COVID-19) experience a Kawasaki-like illness, called multisystem inflammatory syndrome in children (MIS-C). The complication is akin to toxic shock syndrome, a condition that occurs due to sepsis. Though rare, the condition is life-threatening.

29 May 2020

Research provides important insights into genetic adaptation of SARS-CoV-2 to humans

In their groundbreaking paper available on the preprint server medRxiv, University of Pittsburgh researchers were appraising signals of SARS-CoV-2 genome evolution and found that purifying selection (i.e., removal of deleterious mutations) represents the dominant trait during early coronavirus disease (COVID-19) pandemic - suggesting that the virus will evolve as it diversifies in a growing number of hosts.

28 May 2020

ACE2 receptors in the kidney not linked to high BP or RAS blockers

Even as the COVID-19 pandemic continues to smolder and flare up in various parts of the world, researchers are still trying to make sense of the virus, its routes of spread, its target tissues, and the immune responses it induces. One crucial piece of knowledge is that the primary viral receptor is a human enzyme called angiotensin-converting enzyme 2 (ACE2).

27 May 2020

Neurological complications of COVID-19: What is known so far?

Researchers at the São Leopoldo Mandic School of Medicine in Brazil have presented a review of the current data available on the neurological effects of coronavirus disease 2019 (COVID-9).

27 May 2020

WHO halts Hydroxychloroquine in COVID-19 trial over safety concerns

The coronavirus disease (COVID-19) has taken a toll on 188 countries and territories across the globe. With the increasing number of confirmed cases, scientists race to develop treatments and vaccines to fight the novel coronavirus.

27 May 2020

What affects the case fatality rate of COVID-19? Analysis of top 50 affected countries

Ever since the beginning of the international spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes COVID-19 disease, researchers have been trying to identify the risk factors that increase the chances of infection. Now, a new study published on the preprint server medRxiv in May 2020 discusses various potential factors and reports the observed associations.

27 May 2020

Study finds very low level of SARS-CoV-2 in two San Francisco Bay areas

A new study published on the preprint server medRxiv in May 2020 reports a very low prevalence of antibodies in two separate populations living in the San Francisco Bay Area.

26 May 2020

Heparin resistance among COVID-19 patients admitted to ICU

A new study has shown that COVID-19 patients admitted to the Intensive care unit may be resistant to the naturally occurring anticoagulant Heparin. The study titled, “Heparin resistance in COVID‑19 patients in the intensive care unit,” was published in the latest issue of the Journal of Thrombosis and Thrombolysis.

26 May 2020

IgG antibodies reduce viral load of SARS-CoV-2

A study conducted by researchers at the University of Washington has highlighted the importance of serological testing for infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

26 May 2020

Zero benefit of Hydroxychloroquine or Chloroquine in COVID-19, says extensive study

The purported "game-changer" anti-malarial drug Hydroxychloroquine, which was claimed to be effective in preventing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and also helping better outcomes in COVID-19 patients, seems to have failed in clinical trials.

25 May 2020

Newly identified gene may have contributed to rapid evolution of COVID-19

An international team of researchers has identified a previously uncharacterized gene within the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) genome that may be important in understanding the origins and evolution of coronavirus disease 2019 (COVID-19).

25 May 2020

New study pinpoints ideal antiviral targets within the SARS-CoV-2 viral cycle

A specific biophysical model for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) shows how potential drugs inhibiting both viral transcription and translation would be particularly effective against coronavirus disease (COVID-19). The model was developed by University of Minnesota researchers and described in their recent publication available on the bioRxiv preprint server.

25 May 2020

Can Chlorpromazine help treat COVID-19?

A new research paper published in the journal L'Encéphale in May 2020 reports on the planned ReCoVery Study, which will examine the possibility of repurposing the antipsychotic drug chlorpromazine for the treatment of COVID-19.

25 May 2020

New biomarkers to consider for SARS-CoV-2 vaccine

Researchers at the University of Melbourne have made new discoveries about how the immune system responds to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that could be important to consider in vaccine research.

24 May 2020

Study evaluates the effectiveness of interferon beta 1b in COVID-19 pneumonia

As the world struggles to overcome the current COVID-19 pandemic with non-pharmacological interventions, in the absence of an effective drug or vaccine, existing immunomodulators are being repurposed. A new study published on the preprint server medRxiv* in May 2020 shows no clinical benefit to the use of one such drug, called interferon beta 1b (IFN beta1b).

22 May 2020